NCT03869697View on ClinicalTrials.gov

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

November 4, 2021

Study Completion Date

November 23, 2021

Conditions
Malignant Pleural Effusions
Interventions
DRUG

SCB-313

5 mg or 20 mg lyophilized powder in a single-use glass vial

Trial Locations (4)

2170

Liverpool Hospital, Liverpool

2800

Orange Health Service, Orange

3050

The Royal Melbourne Hospital, Parkville

6009

SCGH (Sir Charles Gairdner Hospital), Nedlands

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY